Environment

• 100% renewable electricity by 2025 (Scope 2)
• 80% reduction in carbon emissions and investment in nature-based solutions for the remaining 20% of our footprint by 2030 (all scopes)*
• Net zero emissions across our full value chain by 2045 (all scopes)

* Previously stated as net zero by 2030, and updated to align with the SBTI Net Zero Standard. See page 16 of the 2022 ESG Performance Report for more context.

Water

• 100% of our sites to achieve good water stewardship by 2025 and reduce overall water use by 20% by 2030

• Water neutral in operations and with key suppliers in water-stressed regions by 2030

• Zero impact active pharmaceutical ingredient levels ⁽¹⁾ for all sites and key suppliers by 2030

Waste and materials

• Zero operational waste ⁽²⁾, including eliminating single use plastics⁽³⁾ by 2030

• 25% environmental impact reduction for our products and packaging by 2030

• 10% waste reduction from supply chain by 2030

Biodiversity

• Positive impact on biodiversity at all sites ⁽⁴⁾ by 2030

• 100% of agricultural, forestry and marine derived materials sustainably sourced and deforestation free by 2030 ⁽⁵⁾

¹ Below the predicted no-effect level 
² Including a 20% reduction in routine hazardous and non-hazardous waste
³ Where regulatory obligations allow, and excluding plastics which are critical to product discovery and development and health & safety
⁴ GSK-owned sites 
⁵ Target updated in December 2021 to reflect priority materials

Delivering our climate and nature goals is now a fundamental part of our business. That’s why we continue to integrate sustainability into our operations.

Achieving these new goals will require collaboration across our entire value chain – from discovery to disposal - and so we will continue to work closely on sustainability with our suppliers, customers, consumers, patients and external experts.

Beyond the impact we have on the environment, we are also helping to adapt and build resilience to the new health challenges that a changing environment will bring. We’re doing this by developing and manufacturing new medicines and vaccines for the diseases most affected by climate change. We’re also playing our part in building strong health systems, especially in locations that are most vulnerable to climate-related shocks.

Global health

Our climate strategy covers the full value chain of emissions reductions across our own operations, our supplier base and emissions from patient use of our products.

We have set out a projected pathway to reaching net zero carbon by 2030 and identified the key activities that will help us reach this goal. 

The Science Based Targets Initiative has accredited that our climate targets align to a 1.5° pathway. We have joined the Race to Zero: a global UN campaign, which aims to build momentum around the shift to a decarbonised economy. We have also disclosed climate change risks aligned to the Taskforce for Climate-related Financial Disclosure (TCFD) since 2019 – see our climate related financial disclosure as part of our Annual report.

Measuring and accounting for how companies impact the natural world is an emerging field. We are collaborating with partners to understand how best to measure our nature impacts and meet industry standards, for example working with the World Business Council of Sustainable Development and the UN Environment Programme to contribute to the Science Based Targets Network for nature.

We will align to the Science Based Targets Network approach to measure our impact on nature and will seek to accredit our target when the methodology is finalised.

We have set a clear goal to be net positive on nature by 2030. To find out more about our how we plan to deliver these goals across our business, please see our water, materials and waste, and biodiversity pages.